New combo treatment trial targets rare blood cancer

NCT ID NCT07380984

Recruiting now Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

Summary

This study is testing a personalized treatment approach for people with early-stage NK/T-cell lymphoma, a rare blood cancer. Researchers are combining an immunotherapy drug (PD-1 antibody) with radiation therapy, adjusting treatment based on how patients respond. The goal is to improve survival rates while reducing treatment side effects for this difficult-to-treat cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NATURAL KILLER/T-CELL LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ruijin Hospital, Shanghai JiaoTong University School of Medicine
RECRUITING

Shanghai, China

Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.

NATURAL KILLER/T-CELL LYMPHOMA